Fred Aslan - 05 Mar 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role: President and CEO, Director
Signature: /s/ Neha Krishnamohan, Attorney-in-Fact
Issuer symbol: ARTV
Transactions as of: 05 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 07 Mar 2025, 16:35:00 UTC
Previous filing: 18 Jul 2024
Next filing: 18 Aug 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARTV	Common Stock	Award	$0	+200,000	+92%	$0.000000	416,665	05 Mar 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
F2	Reflects reduction in the number of shares subject to the RSU granted on July 22, 2024 from 228,905 shares to 216,665 shares. The equity award was originally calculated based on the maximum offering size of the Company's initial public offering (IPO) and such award was subsequently adjusted following the partial exercise of the underwriters option to purchase additional shares in connection with the IPO.

Content

Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

Reflects reduction in the number of shares subject to the RSU granted on July 22, 2024 from 228,905 shares to 216,665 shares. The equity award was originally calculated based on the maximum offering size of the Company's initial public offering (IPO) and such award was subsequently adjusted following the partial exercise of the underwriters option to purchase additional shares in connection with the IPO.